Phase II trial to topotecan in hepatocellular carcinoma: A southwest oncology group study

Investigational New Drugs

Volumn 15, Issue 3, 1997, Pages 257-260

  Wall, James G ^a   Benedetti, Jacqueline K ^b   O'Rourke, Mark A ^c   Natale, Ronald B ^d   Macdonald, John S ^e  

^a Carolinas Medical Center NorthEast   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e TEMPLE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Phase II trial; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA; TOPOTECAN;

EID: 0030659116     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005851804533     Document Type: Article

References (8)

1. Lotze MT, Flickinger JC, Carr BI: Hepatobiliary Neoplasms. In: Devita V, Hellman S, Rosenberg S (eds) Cancer: Principles and Practice of Oncology, 4th ed. JB Lippincott Co., Philadelphia, 1993, pp 883-914.
2. Luporini G, Labianca R, Pancera G: Medical treatment of hepatocellular carcinoma. J Surg Oncol Suppl 3: 115-118, 1993.
3. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20: 73-96, 1994.
4. Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG: SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. (Abstract) Proc Amm Assoc Cancer Res 30: 623, 1989.
5. Wall J, Burris H, Von Hoff D, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. AntiCancer Drugs 3: 337-345, 1992.
6. Rowinsky E, Grochow L, Hendricks C, Ettinger D, Forastiere A, Hurowitz L, McGuire W, Sartorius S, Lubejko S, Kaufmann S, Donehower R: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656, 1992.
7. Sirott M, Saltz L, Young C, Tong W, Trochanowski B, Niedzwiecki D, Toomasi F, Kelsen D: Phase I and clinical pharmacologic study of intravenous topotecan (T). (Abstract) Proc Am Soc Clin Oncol 10: 104, 1991.
8. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Von Hoff D, Garteiz D, Raber M: A phase I trial of topotecan (TOPO) administered by a 24-hour infusion. (Abstract) Proc Amer Assoc Cancer Res 32: 206, 1991.